Abstract: FR-PO861
Baseline Characteristics and Associations of Using SGLT2 Inhibitors in IgA Nephropathy in China: Results from the CPO-IGAN
Session Information
- IgA Nephropathy: Clinical, Outcomes, and Therapeutics
October 25, 2024 | Location: Exhibit Hall, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Glomerular Diseases
- 1402 Glomerular Diseases: Clinical, Outcomes, and Therapeutics
Authors
- Chen, Chaosheng, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China
- Zhang, Ji, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China
- Jiang, Gengru, Shanghai Jiaotong University School of Medicine Xinhua Hospital, Shanghai, China
- Wang, Rong, Shandong Provincial Hospital, Jinan, Shandong, China
- Zhao, Chuanyan, Northern Jiangsu People's Hospital, Yangzhou City, Jiangsu Province, China
- Chen, Qinkai, First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China
- Chen, Min, Chengdu First People's Hospital, Chengdu, Sichuan, China
- Xue, Hen, Ya'an People's Hospital, Ya'an, Sichuan, China
- Wang, Niansong, Shanghai 6th Peoples Hospital Affiliated to Shanghai Jiao Tong University, Shanghai, China
- Fan, Qiuling, Shanghai General Hospital, Shanghai, Shanghai, China
- Qiu, Guoping, Jiujiang First People's Hospital, Jiujiang, Jiangxi, China
- Ma, Hongbo, Zibo Central Hospital, Zibo, Shandong, China
- Yu, Lixia, Kunshan First People's Hospital, Kunshan, Jiangsu, China
Background
IgA nephropathy (IgAN) is most common primary glomerular disease in China. The 2024 KDIGO CKD guideline recommends Sodium-glucose co-transporter 2 inhibitors (SGLT2i) as first-line treatment for CKD.SGLT2i use in Chinese IgAN patients is understudied. The Clinical Practice Optimization Initiative for Chinese Patients with IgA Nephropathy (CPO-IGAN) is the first nationwide project with the aim of optimizing clinical practices in IgAN across China.
Methods
As of March, 2024 we recruited 2783 IgAN patients from 33 hospitals across 12 provinces. And for the SGLT2i sub-group, we have extracted and analyzed the data pertaining to IgAN patients administered with SGLT2i.
Results
In total, 2264 Primary IgAN patients were included, 100 of whom had initiated SGLT2i therapy at the baseline: The median age was 42 years, 46% were females and the median (IQR) of eGFR was 88.29 mL/min/1.73 m2 and 24-hour urinary protein was 1269 mg/day (Table 1).The non-SGLT2i group and SGLT2i group, mainly differing in age,the initial treatment post-diagnosis and comorbidity(Table 1).More than half of patients using SGLT2i were concentrated in 2023(51%).A logistic regression analysis indicated that the clinician's selection of SGLT2i was correlated with comorbidity of Type 2 diabetes (OR = 11.82, P < 0.001) (Table 1).Post-follow-up effects of SGLT2i is undergoing.
Conclusion
This study indicates that SGLT2i were used in IgAN patients in China. The association of SGLT2i using with diabetic status suggests that nephrologist may consider SGLT2i more as a diabetes medication than as a treatment for CKD. The critical need for enhancing clinician awareness and education about SGLT2i's benefits for IgAN patients.
Funding
- Clinical Revenue Support